Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study

Vincenzo Arena, Giovanni Scambia, Arnaldo Carbone, Gf Zannoni, Vg Vellone, Mg Prisco, D. Gallo

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

This study was aimed at determining whether high-grade endometrioid carcinomas (grade 3 International Federation of Gynecology and Obstetrics) might overlap, at least partially, non-endometrioid carcinomas (type II). To this end, a panel of clinical-pathological and immunohistochemical parameters was evaluated in three different populations: low-grade endometrioid carcinomas (LGECs; n = 57), high-grade endometrioid carcinomas (HGECs; n = 26), and non-endometrioid carcinomas (NECs; n = 30). Besides morphological appearance, HGECs appeared similar to LGECs in p53 immunostaining profile; features different from LGECs included a higher local aggressiveness, a higher invasion of lymph-vascular spaces, a lower expression of ERalpha and PR, and a higher proliferative index. HGECs were similar to NECs for local aggressiveness, invasion rate of lymph-vascular spaces, lymph node metastasis incidence, and proliferative index. HGECs, however, showed a lower rate of extra-nodal metastases, a lower incidence of p53 overexpression, and a higher positivity for ERalpha and PR. In conclusion, results from this study show that HGECs exhibit overlapping morphological and immunohistochemical features of both type I and type II endometrial carcinomas. Further research is needed to clarify the clinical value of this observation.
Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalVirchows Archiv : an international journal of pathology
Volume457
DOIs
Publication statusPublished - 2010

Keywords

  • Carcinoma, Endometrioid
  • Endometrial Neoplasms
  • Female
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen
  • Middle Aged
  • Neoplasm Staging
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tumor Markers, Biological
  • Tumor Suppressor Protein p53

Fingerprint

Dive into the research topics of 'Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study'. Together they form a unique fingerprint.

Cite this